Alnylam, MIT Team Publishes Report on Non-Lipid Nanoparticles as siRNA Delivery Vehicles

Notably, Alnylam in recent months has been promoting its efforts to develop new delivery approaches amid a legal battle with Tekmira Pharmaceuticals over the rights to a key lipid nanoparticle technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.